We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Creo Medical Group Plc | LSE:CREO | London | Ordinary Share | GB00BZ1BLL44 | ORD GBP0.001 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 0.72% | 34.75 | 34.50 | 35.00 | 34.75 | 34.50 | 34.50 | 73,412 | 14:20:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Surgical,med Instr,apparatus | 27.17M | -26.94M | -0.0746 | -4.66 | 125.53M |
TIDMCREO
RNS Number : 4135B
Creo Medical Group PLC
09 January 2018
Creo Medical Group plc
Director/PDMR Dealing
The Company announces that on 9 January 2018, Steven Morris, Chief Operating Officer and a PDMR, transferred 115,000 ordinary shares from his personal holding to his self-invested personal pension (SIPP) at a price of 68.0p per share. Furthermore, his SIPP purchased an additional 325 ordinary shares in the Company at a price of 68.0p per share. Following these transactions, Mr Morris's total interest in ordinary shares is 115,325 ordinary shares.
Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1 Details of the person discharging managerial responsibilities / person closely associated --- ------------------------------------------------------------ a) Name Steven Morris --- ------------------------- --------------------------------- 2 Reason for the notification --- ------------------------------------------------------------ a) Position/status Chief Operating Officer --- ------------------------- --------------------------------- b) Initial notification Initial /Amendment --- ------------------------- --------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor --- ------------------------------------------------------------ a) Name Creo Medical Group plc --- ------------------------- --------------------------------- b) LEI 213800H188ZDCWWXFA21 --- ------------------------- --------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted --- ------------------------------------------------------------ a) Description of the financial Ordinary shares of GBP0.001 instrument, type each of instrument Identification GB00BZ1BLL44 code --- ------------------------- --------------------------------- b) Nature of the Transfer of ordinary shares transaction to SIPP via sale and purchase --- ------------------------- --------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) ------------------ ---------- Sale of shares from personal holding at 68.0p per share 115,000 ------------------ ---------- Purchase by SIPP at 68.0p per share 115,325 ------------------ ---------- --- ------------------------- --------------------------------- d) Aggregated information - Aggregated volume - Price Weighted average price of 68.0 pence per share --- ------------------------- --------------------------------- e) Date of the transaction 9 January 2018 --- ------------------------- --------------------------------- f) Place of the transaction London Stock Exchange --- ------------------------- ---------------------------------
Contacts
Creo Medical: Cenkos: FTI Consulting: Richard Rees Camilla Hume/Mark Brett Pollard +44 (0)129 160 6005 Connelly (NOMAD) / Mo Noonan Richard.Rees@creomedical.com Michael Johnson +44 (0)203 727 / Russell Kerr 1000 (Sales) creo@fticonsulting.com +44 (0)207 397 8900
About Creo Medical
Creo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. The Company's mission is to improve patient outcomes by applying microwave and radiowave energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical platform that combines bipolar radiofrequency for precise localised cutting and microwave for controlled coagulation. This technology provides physicians with flexible, accurate and controlled surgical solutions.
The Company's strategy is to bring its CROMA platform to market through a suite of medical devices which the Company has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. The CROMA platform will be developed further for bronchoscopy and laparoscopy procedures. The Company believes its technology can impact the landscape of surgery and endoscopy by providing safer, less-invasive and more cost-efficient option of treatment.
For more information about Creo Medical please see our website, www.creomedical.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFFDLSIAIIT
(END) Dow Jones Newswires
January 09, 2018 12:43 ET (17:43 GMT)
1 Year Creo Medical Chart |
1 Month Creo Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions